Incyte stock
INCYNASDAQIncyte Corporation, HealthcareISIN US45337C1027
70Score 70 out of 100, Strong
Price and trend
85 / 100
Price history
+13% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 12% above it.
Since July 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is 5.9% below its 52-week high. Largest decline in 20 years: 83% (February 2008 to March 2009).
Chart figures for advanced users
- SMA 50$119.46
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$108.71
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$90.30
- The lowest closing price of the last twelve months.
- Resistance$129.93
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Incyte Corporation belongs to the Biotechnology industry (United States) and, with a market value of $24.92B, is number 16 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $5.14B (up 21.2% year on year) and earnings of $1.29B (up 3,845%).
- For fiscal 2026, analysts expect on average revenue of $6.04B (up 17.5%) and adjusted earnings per share of $3.21 (down 52.7%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 140 of 714 in Healthcare, median 53.
- The P/E is 61.6 (Biotechnology median 21.3, own median of recent years 42).
- Our model puts fair value at $58.11, with the price 110% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 69.4% in fiscal 2025, Biotechnology median −24.3%.Profitability 66
- Analysts expect strong earnings growthUp 49% a year through 2028 (estimates from 16 analysts).Growth 65
- More cash than debtCash $3.85B, financial debt $37.41M.Stability 90
Weaknesses
- Above fair valuePrice 110% above the fair value of $58.11.Valuation 14
- Richly valuedP/E 61.6, Biotechnology median 21.3, own median 42.Valuation 14
Its standout strengths are stability and technical analysis, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- calm price action
- price near its 52-week high
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $44.70 and expensive above $83.01 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $73.96 (cash-flow model) and $42.26 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $52.85, at 8.2% it would be $65.71.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 24.9% on the twelve months before. Revenue has grown strongly since 2006, at around 32% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 93%, operating 26%, net 25%. Last 12 months: net 7%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 9 Feb 2027in 89 days
- Last reported
- 29 Oct 2026EPS reported −$3.60 (expected −$3.93)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 3.8% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $3.21−3.8%
- Revenue
- $6.04B+1.7%
- Earnings per share
- $8.16−0.3%
- Revenue
- $6.28B+0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.0%Incyte raised its full-year sales guidance to $5.21 to $5.30 billion, along with higher guidance for OPZELURA and hematology and oncology.
The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $48.89M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Stein Steven HSale
6 Nov 2026, CMO & Head of Late-Stage Dev.
- Shares
- 240,193
- Price
- $118.39
- Value
- $28.44M
- Tray ThomasSale
3 Nov 2026, Principal Accounting Officer
- Shares
- 610
- Price
- $118.96
- Value
- $72,566
- Cagnoni Pablo JSale
15 Oct 2026, President, Global Head of R&D
- Shares
- 2,642
- Price
- $112.71
- Value
- $297,780
Show 14 more
- Cagnoni Pablo JSale
15 Sept 2026, President, Global Head of R&D
- Shares
- 23,218
- Price
- $120.49
- Value
- $2.8M
- Cagnoni Pablo JSale
19 Aug 2026, President, Global Head of R&D
- Shares
- 10,801
- Price
- $125.56
- Value
- $1.36M
- Cagnoni Pablo JSale
12 Aug 2026, President, Global Head of R&D
- Shares
- 10,803
- Price
- $120.04
- Value
- $1.3M
- Cagnoni Pablo JSale
5 Aug 2026, President, Global Head of R&D
- Shares
- 10,640
- Price
- $122.69
- Value
- $1.31M
- Mayes Patrick ASale
5 Aug 2026, EVP & Chief Scientific Officer
- Shares
- 2,207
- Price
- $123.99
- Value
- $273,646
- Mayes Patrick ASale
3 Aug 2026, EVP & Chief Scientific Officer
- Shares
- 6,055
- Price
- $120.43
- Value
- $729,204
- Cagnoni Pablo JSale
31 Jul 2026, President, Global Head of R&D
- Shares
- 15,888
- Price
- $119.70
- Value
- $1.9M
- Mayes Patrick ASale
31 Jul 2026, EVP & Chief Scientific Officer
- Shares
- 41,899
- Price
- $119.46
- Value
- $5.01M
- Stein Steven HSale
16 Jul 2026, CMO & Head of Late-Stage Dev.
- Shares
- 1,877
- Price
- $114.73
- Value
- $215,348
- Issa Mohamed KhairieSale
16 Jul 2026, EVP, Head of U.S. Commercial
- Shares
- 1,093
- Price
- $115.01
- Value
- $125,706
- Stein Steven HSale
15 Jul 2026, CMO & Head of Late-Stage Dev.
- Shares
- 28,237
- Price
- $113.05
- Value
- $3.19M
- Tray ThomasSale
4 Jun 2026, Principal Accounting Officer
- Shares
- 2,639
- Price
- $100.00
- Value
- $263,900
- Tray ThomasSale
26 May 2026, Principal Accounting Officer
- Shares
- 2,051
- Price
- $97.35
- Value
- $199,665
- Clancy Paul JSale
19 May 2026, Board
- Shares
- 15,000
- Price
- $94.93
- Value
- $1.42M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Incyte
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Roivant SciencesROIV $30.32B47
- InsmedINSM $26.49B43
- WuXi Biologics (Cayman)2269.HK $25.42B73
- United TherapeuticsUTHR $25.37B81
- BioNTechBNTX $21.73B37
- Alnylam PharmaceuticalsALNY $21.41B57
- Innovent Biologics1801.HK $19.29B61
- ExelixisEXEL $17.77B90
ETFs that hold Incyte
Held by 124 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.39% | 0.49% | €26.29M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.65% | 0.49% | €318.39M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.57% | 0.35% | €1.21B |
Show 5 more
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 1.25% | 0.25% | €44.3M |
| Global X S&P 500 Covered Call UCITS ETF IncXY7D | 0.67% | 0.45% | €203.27M |
| Invesco Global Active ESG Equity UCITS ETFIQSE | 0.63% | 0.30% | €3.11B |
| iShares Ageing Population UCITS ETF2B77 | 0.57% | 0.40% | €807M |
| Xtrackers MSCI World Minimum Volatility UCITS ETF 1CXDEB | 0.44% | 0.25% | €1.38B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.